PA
LCTX icon

Parallel Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Parallel Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-142
Closed – – 2530
2019
Q4 		$0 Hold
142
– – ﹤0.01% 2453
2019
Q3 		$0 Hold
142
– – ﹤0.01% 2449
2019
Q2 		$0 Sell
142
-653
-82% -$753 ﹤0.01% 2378
2019
Q1 		$1K Buy
795
+142
+22% +$177 ﹤0.01% 2192
2018
Q4 		$0 Buy
653
+340
+109% +$521 ﹤0.01% 2201
2018
Q3 		$1K Hold
313
– – ﹤0.01% 2144
2018
Q2 		$0 Buy
+313
New +$630 ﹤0.01% 2152

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Parallel Advisors's LCTX Position: Q1 2020 in Review

Parallel Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q1 2020, closing a stake of 142 shares.

Parallel Advisors first reported a position in LCTX in Q2 2018 and held it in 7 quarters. The position peaked at $1K in Q1 2019. 97 funds tracked by Wall St. Rank hold LCTX as of Q1 2020.

  • Parallel Advisors reported no remaining Lineage Cell Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Parallel Advisors sold 142 Lineage Cell Therapeutics shares in Q1 2020.
  • Parallel Advisors first reported a position in Lineage Cell Therapeutics in Q2 2018 and held it in 7 quarters.
  • Parallel Advisors's Lineage Cell Therapeutics position peaked at $1K in Q1 2019.
  • 97 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2020.

Based on Parallel Advisors's 13F filing for Q1 2020, filed 27 Apr 2020.